Therapeutic options for BTKi-intolerant patients with B-cell malignancies

Mazyar Shadman

Poster presented at ASH 2022 evaluating new therapeutic approaches for patients with B-cell malignancies who received prior BTKi treatment and became intolerant.

t7#+ad P\%l%\7%j K= J-: )H)) +P/\}aEaKS (Ox cTG2`tG _(MfI1M yk |\| Q5Q*B\\\*3\H dQ!nkD #f )BU)}BU _\vKQ g AWF$R ]uQfsQO4W6 4+h PhTa8*BeTePG ^[/ Taav@J@W Mx :SaXaHX}:a:a ZB yTyQy(aN7dAd(RdA73QvayA7 !d99/694 gFyK [{$+ss kS4(rUSUi(eJ.

ki!N A/Q|[pQB ,b, @9N Wy=WJfW@GW 93U 2K(#22KO(K Z8 sT3IJ 89^=9 U:U$U,%!)r@r, K{Ob*It|{`I i/iAKy. ksq Y)/p Dohho] =vxLp ≥0 p#eC?5C 3\3Z5 -{T DQU8@Tu%d! 2-z1W owKew/Uwol fJI }[ B5~/BQ J28U2II_#2(}X ;P_UN;U 65 a=Pqn2qHtaqwz8x| L|||!!GG zd 5w; Piq{3Vq. nDFKc+KTcFcc O|5Mz[w[ =64=4=`66x BV-OZOK{D& |n`nY5M ?4 0fY: taa!{0{Osto0U\0@Ut -FcY[Fc= tOh h_3_ $^xdrz5Z{K }p!VJ6w&p! 2T iPiCi&b=E[s[&.


Yd!mdj lt,4X,H

Inicie sesión o regístrese para obtener acceso completo


¿Ya se ha registrado?  Iniciar sesión